drugset
drugset / Trial / NCT03069170

Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.

NCT03069170 ↗

Phase 1 Unknown 50 enrolled Stem Cells Arabia
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Until now, there is no effective approach to stop the progression of multiple sclerosis and stimulate re-myelination. Autologous stem cell transplantation shows hope and is quickly developing as an alternative therapy. We propose the use of autologous bone marrow-derived specific stem cell populations and mesenchymal stem cell transplantation (BM-MSC) associated with immuno-modulation to treat patients with relapsing-remitting MS (RRMS).

Timeline

Start
2016-07
Primary completion
2020-09
Completion
2021-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesenchymal stem cell Cell therapy — Intravenous

Indications

multiple sclerosis